James Christensen

James Christensen is the EVP and Chief Scientific Officer at Mirati Therapeutics. James has over 25 years of experience in the pharmaceutical industry, including in cancer research and development.

Christensen began their career at Warner Lambert/Agouron/Pfizer, where they worked for six years on oncology precision medicine. James then spent three years as a group leader at SUGEN before joining Pharmacia Corporation as a team leader.

In 2003, Christensen joined Pfizer, where they spent 10 years in various roles, including Sr. Director of the TORCH collaboration and Sr. Director of Oncology Precision Medicine. In 2013, they left Pfizer to join Mirati Therapeutics.

At Mirati, Christensen is responsible for leading the company’s scientific and clinical strategy. James has played a key role in the development of several of Mirati’s lead cancer drugs, including sitravatinib and mocetinostat.

Their manager is David Meek, CEO & Director. Thian Kheoh - VP, Biometrics, Matthew Marx - VP, Head of Drug Discovery report to James Christensen. Some of their coworkers include Reena R. Desai - VP, General Counsel & Corporate Secretary, Allen Albright - VP, Regulatory Affairs & Quality Assurance, and Ryan Asay - VP, Corporate Affairs.